What does Varex Imaging do?
Varex Imaging Corporation is a Nasdaq-listed manufacturer of components used in medical, security, and industrial X-ray systems. Varex supplies tubes, detectors, software, and interconnect products that OEMs integrate into medical, security, and industrial imaging equipment. Its official company profile describes Varex as a leading independent supplier.
Which components sit inside customer systems?
Medical tubes create the X-ray beam; Linatron accelerators support cargo and industrial inspection.
Detectors convert X-ray energy into digital data across several sensor technologies.
Interconnects, collimators, cooling, reconstruction software, and image-processing tools support complete platforms.
Why does the independent-supplier position matter?
Large imaging OEMs can make components internally, but maintaining tube, detector, software, and high-voltage technologies is capital intensive. Varex offers a broad outsourced alternative. Its FY2025 Form 10-K reports production of more than 27,000 X-ray tubes and 20,000 detectors annually, plus an installed base exceeding 160,000 tubes, 170,000 detectors, 600,000 connect-and-control components, and 16,500 software instances. That base supports replacement and service demand, although the core model remains product manufacturing.
| Identity item | Varex detail | Research implication |
|---|---|---|
| Listing | Nasdaq: VREX | A single-class public company rather than an OEM-controlled subsidiary. |
| Industry role | X-ray imaging components and selected industrial systems | Performance depends on OEM design wins, replacement demand, product yield, and manufacturing execution. |
| Primary customers | Medical-equipment OEMs, security integrators, industrial manufacturers, and government-linked inspection programs | Customer concentration and long qualification cycles are central to both the moat and the risk profile. |
| Geographic model | Manufacturing, engineering, service, and sales across North America, Europe, and Asia | The global footprint diversifies demand but introduces tariffs, currency exposure, export controls, and local-sourcing pressure. |
How does Varex Imaging make money?
Varex earns most revenue by shipping hardware to OEMs and system integrators. Pricing reflects specifications, volume, contracts, warranties, and customization. Service, replacements, and software add recurring elements, but the engine is winning an OEM platform and supplying it over time.
How do the Medical and Industrial economics differ?
| Segment | FY2025 revenue | Revenue logic | Margin logic |
|---|---|---|---|
| Medical | $592.6M; 70.2% of FY2025 total | OEM production, replacement tubes, detectors, software, and accessories across CT, radiography, fluoroscopy, oncology, mammography, dental, and veterinary modalities. | High volumes help absorb fixed costs, but powerful OEM customers and in-house alternatives constrain pricing. |
| Industrial | $252.0M; 29.8% of FY2025 total | Cargo and border systems, baggage screening, industrial tubes, detectors, linear accelerators, inspection software, and service agreements. | Generally higher gross-margin potential because products are specialized, pricing is more favorable, and Medical R&D and manufacturing scale can be reused. |
What converts a design win into cash flow?
Design-ins can last decades because supplier changes require validation and reliability work. They also create a working-capital burden because Varex holds materials before shipment. Backlog was approximately $262 million at October 3, 2025, but orders can be revised or canceled.
Which products, regions, and customers matter most?
Medical supplies scale; Industrial supplies diversification and typically better gross-margin potential. In FY2025, Medical revenue increased 2% and Industrial revenue 10%. CT, oncology, mammography, security-inspection products, tubes, and detectors drove the gains, partly offset by weaker radiography, veterinary, and dental demand.
How concentrated is the segment mix?
Where does geographic and customer concentration appear?
The United States generated $254.9 million of FY2025 revenue, Japan $143.5 million, and China $128.3 million, or about 15% of the total. Customer concentration is sharper: Canon represented about 18%, the top five about 40%, and the top ten about 52%. Some large OEMs simultaneously buy from Varex, manufacture internally, and compete in external sales.
What strategic turning points shaped Varex Imaging?
Varex is a young public company built on an older X-ray engineering base. Its useful history is the sequence that created today’s mix of tubes, detectors, software, photon counting, and industrial systems.
From Varian roots to a broader component platform
-
1948 onwardThe business developed within Varian, creating decades of tube engineering and OEM relationships.
-
2015A controlling interest in MeVis added image-processing software and cancer-screening expertise.
-
January 2017Varex separated from Varian Medical Systems, enabling independent capital allocation for imaging components and industrial applications.
-
May 2017PerkinElmer imaging assets expanded detector products, manufacturing, and customer reach.
-
April 2019Varex acquired about 98% of Direct Conversion, adding photon-counting technology; the remainder followed in 2021.
-
FY2025Industrial revenue reached $252.0 million and 29.8% of company revenue, while a $93.9 million Medical goodwill impairment highlighted the pressure on expected returns from prior investments.
-
March–July 2026Varex refinanced debt to 2031 and advanced the Pyxis photon-counting CT platform.
Why is photon-counting technology strategically important?
Photon-counting detectors count individual photons and separate energy levels, supporting higher spatial resolution, material differentiation, and dose efficiency. Varex’s Pyxis photon-counting CT platform is designed to combine detector hardware with real-time corrections so OEMs can reduce integration complexity. The strategic prize is becoming embedded in next-generation CT architectures before volume production.
What does Varex Imaging’s latest quarter show?
The latest reported period was the quarter ended April 3, 2026, Varex’s second quarter of fiscal 2026. Its Q2 FY2026 earnings release showed modest revenue growth, lower gross margin, a refinancing-related GAAP loss, and heavier working-capital use.
Q2 FY2026 financial snapshot
| Metric | Q2 FY2026 | Q2 FY2025 | Interpretation |
|---|---|---|---|
| Revenue | $216.0M | $212.9M | Growth was modest but positive, supported by global CT, cargo systems, and photon-counting detectors. |
| Medical revenue | $156.2M | $153.8M | Radiography, CT, mammography, and other modalities offset weakness in fluoroscopy, dental, veterinary, and oncology. |
| Industrial revenue | $59.8M | $59.1M | Digital-detector gains were partly offset by lower inspection-product and component sales. |
| Gross profit / margin | $72.6M / 33.6% | $76.7M / 36.0% | Medical gross margin fell to 32.4%, while Industrial improved to 36.8%. |
| Operating income / margin | $14.4M / 6.7% | $22.1M / 10.4% | Lower gross profit and higher SG&A reduced operating leverage. |
| Diluted EPS | $(0.19) | $0.17 | The quarter included $9.4M of debt-extinguishment costs within interest expense. |
| R&D | $22.2M; 10.3% of revenue | $22.0M; 10.3% | Investment remained near management’s long-run 8%–10% target range. |
What changed beneath the revenue line?
Operating cash outflow was about $2 million in Q2 FY2026 and $17.6 million for the first half. Inventory rose to $346.7 million at April 3, 2026 for anticipated shipments. If customer timing slips, cash remains trapped in stock. The filed Q2 FY2026 Form 10-Q is more cautious than the revenue headline.
X-ray component scale, integration, and installed base create the moat
Varex lacks a consumer brand or software network effect. Its advantage is industrial: engineering knowledge, production scale, qualification history, an installed base, and multiple parts of an X-ray architecture. Tube life, detector quality, dose, resolution, heat management, uptime, and documentation directly affect the OEM’s product.
How does manufacturing scale reinforce reliability?
High volumes spread engineering, tooling, facilities, and quality costs. Manufacturing mastery also affects yield and product life, which new entrants cannot establish quickly. Sites use ISO 13485 for medical devices or ISO 9001 for industrial products across the United States, Europe, the Philippines, China, and India. The footprint adds support and capacity but complicates compliance.
Why do integration and switching costs matter?
The installed base reinforces the advantage because replacement parts must match existing systems. The moat is not absolute: lower-cost suppliers, OEM in-sourcing, and new technologies can erode it. Varex must therefore spend continuously on product life, noise reduction, dose efficiency, image resolution, photon counting, and lower-cost manufacturing. FY2025 R&D was $91.1 million, or 10.8% of revenue, so the moat requires recurring reinvestment.
Who competes with Varex, and where is pressure strongest?
Competition differs by component. Medical tubes face OEM in-house operations and outside suppliers. Detector rivals include Trixell, Canon, Vieworks, Hamamatsu, iRay, and CareRay. Industrial rivals include Teledyne, Comet, Nuctech, Siemens, ETM, and PMB Alcen; security integrators can be customers and competitors.
How does Varex position itself against rivals?
| Competitive arena | Named competitors or alternatives | Varex advantage | Pressure point |
|---|---|---|---|
| Medical X-ray tubes | OEM in-house production, Canon, Philips, emerging manufacturers | Tube engineering depth, production scale, installed base, broad modality coverage | OEMs can shift more volume internally or demand price concessions. |
| Medical detectors | Trixell, Canon, Vieworks, Hamamatsu, iRay, CareRay | Multiple detector technologies and integration with software and other components | Rapid product cycles and aggressive Asian competition can compress prices. |
| Industrial low energy | iRay, Teledyne, Comet, specialized suppliers | Medical-derived R&D, broad applications, components plus software | Niche suppliers can be faster or lower cost in a specific vertical. |
| High energy and cargo | Nuctech, Siemens, ETM, PMB Alcen; system integrators | Linatron installed base, service agreements, sources plus selected full systems | Government procurement is lumpy, geopolitical, and price sensitive. |
Entry barriers are meaningful because manufacturing is capital intensive and reliability knowledge compounds. Supplier power is significant where components come from limited sources. Buyer power is high because major OEMs purchase large volumes and can integrate vertically. Varex’s best defense is deeper integration and lower lifecycle cost, not price alone.
How strong are cash flow, liquidity, and capital allocation?
Varex produces operating cash, but inventory and debt costs weakened conversion. FY2025 included a noncash $93.9 million Medical goodwill impairment, signaling weaker expected returns.
What does the annual baseline say about earnings quality?
| Financial measure | FY2025 | FY2024 | What it signals |
|---|---|---|---|
| Revenue | $844.6M | $811.0M | 4.1% growth restored part of the decline experienced in FY2024. |
| Gross profit / margin | $290.5M / 34.4% | $256.9M / 31.7% | Mix and operating conditions improved, with Industrial making a larger contribution. |
| R&D | $91.1M / 10.8% | $87.0M / 10.7% | Technology investment remained structurally high. |
| Operating income (loss) | $(27.8)M | $32.1M | The FY2025 goodwill impairment overwhelmed underlying operating profit. |
| Operating cash flow | $41.7M | $47.3M | Cash generation remained positive but inventory absorbed more cash. |
| Inventory | $299.4M at Oct. 3, 2025 | $264.8M at Sept. 27, 2024 | Higher stock can support shipments, but it increases obsolescence and forecast risk. |
How did the 2026 refinancing change the balance sheet?
On March 13, 2026, Varex replaced its 7.875% secured notes with a $350 million term loan, a $100 million revolver, and up to $40 million of delayed-draw capacity, maturing in March 2031. Debt fell to $347.6 million at April 3, 2026, but refinancing created a $9.4 million charge and retained SOFR exposure.
Capital allocation favors debt, manufacturing, and product development. The key test is inventory conversion. Days sales outstanding improved to 62 days at October 3, 2025 from 70 days a year earlier.
Who owns Varex stock, and how is it governed?
Varex has one voting class, no founder control, and a dispersed institutional base. The latest 2026 proxy statement used 41,919,432 shares outstanding at December 15, 2025 for beneficial-ownership calculations. Influence therefore runs through board elections, compensation votes, institutional engagement, and management ownership.
What do the major holders and governance rules signal?
| Holder or group | Shares | Ownership | Source period | Why it matters |
|---|---|---|---|---|
| Pzena Investment Management | 4,244,977 | 10.1% | Proxy data as of Dec. 15, 2025 | A value-oriented active manager was the largest disclosed holder. |
| BlackRock | 3,364,703 | 8.0% | Proxy data as of Dec. 15, 2025 | Large passive and institutional voting presence. |
| Vanguard | 2,989,847 | 7.1% | Proxy data as of Dec. 15, 2025 | Reinforces broad institutional ownership and governance scrutiny. |
| Allspring Global Investments | 2,554,823 | 6.1% | Proxy data as of Dec. 15, 2025 | Another significant professional manager without controlling power. |
| CEO Sunny Sanyal | 931,092 | 2.2% | Proxy data as of Dec. 15, 2025 | Meaningful economic alignment, but not control. |
| Directors and executive officers as a group | 2,006,570 | 4.6% | 12 persons; Dec. 15, 2025 | Management and board incentives are economically relevant but remain subject to outside shareholders. |
The governance question is whether the board and institutions enforce discipline around acquisitions, leverage, inventory, and R&D returns. The FY2025 impairment makes that oversight especially relevant.
What opportunities, risks, KPIs, and valuation drivers matter most?
X-ray imaging serves healthcare, security, and manufacturing, but qualification can take years. Technology promise must be separated from cash conversion.
Where could growth come from, and what could interrupt it?
Which KPIs belong in a DCF or operating model?
A valuation model should separate segment growth and margins. A one-point gross-margin change on roughly $850 million of revenue changes gross profit by about $8.5 million. Free cash flow requires explicit R&D and inventory assumptions.
May 2026 guidance called for FY2026 revenue of $860 million to $880 million and Q3 revenue of $210 million to $225 million. They are near-term anchors; a DCF must test cash flow after R&D, capex, interest, and working capital.
What is the key takeaway from Varex Imaging analysis?
Varex is an enabling-technology company hidden inside other manufacturers’ imaging systems. Its importance comes from difficult-to-replicate tube and detector engineering, high-volume manufacturing, long OEM relationships, and a large installed base that supports replacement demand. Industrial imaging and photon-counting detectors provide credible avenues to broaden growth beyond traditional medical tubes.
Varex shows how specialized manufacturing creates a moat without an end-user brand. The proof must come through margins and cash conversion. The next phase depends on whether Varex turns its portfolio and innovation spending into returns above the cost of working capital and leverage.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.